Senti Biosciences Holdings, Inc. SNTI
Senti Biosciences Holdings, Inc. (Nasdaq: SNTI) is an oncology drug developer. Its lead program, SENTI-202, is in Phase 1 for Relapsed/refractory hematologic malignancies including acute myeloid leukemia (CD33/FLT3 Logic Gated CAR-NK). Its next catalyst on record is SENTI-202 (Logic Gated off-the-shelf CAR-NK cell therapy): Senti announces CVR milestones for SENTI-202: BLA filing, FDA approval, and $200M net sales by October 2033. (October 2033).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: SENTI-202 (Logic Gated off-the-shelf CAR-NK cell therapy) — Senti announces CVR milestones for SENTI-202: BLA filing, FDA approval, and $200M net sales by October 2033. (October 2033). 5 catalysts on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| SENTI-202 | R/R hematologic malignancies incl. AML (open-label Phase 1, US and Australia; Orphan Drug and RMAT designations) | cell therapy | Phase 1 |
| Solid tumor cell therapy program | Solid tumors | cell therapy | Pre-clinical |
| BlueRock partnered regenerative medicine programs | Regenerative medicine cell therapies (partnered; BlueRock option agreement) | cell therapy | Pre-clinical |
| Rett Syndrome program | Rett syndrome (to be retained by public company if merger closes) | gene therapy | Pre-clinical |
| TIL program | Tumor infiltrating lymphocyte therapy (to be retained by public company if merger closes) | cell therapy | Pre-clinical |
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 1 oncology companies
- Erasca, Inc. ERAS
- Parabilis Medicines, Inc. PBLS
- Xencor Inc XNCR
- Schrodinger, Inc. SDGR
- Vir Biotechnology, Inc. VIR
- Zymeworks Inc. ZYME
- Janux Therapeutics, Inc. JANX
- Aktis Oncology, Inc. AKTS
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.